Preclinical evaluation of PARP inhibition as a treatment for endometrioid endometrial carcinomas.

5065 Background: Loss of function of PTEN is the most common genetic defect in endometroid endometrial carcinomas (EEC). PTEN plays a pivotal role in the regulation of the AKT and mTOR signalling p...